Astellas’ gilteritinib secures EC approval to treat acute myeloid leukaemia

This article was originally published here

Gilteritinib can be used in the treatment of AML patients whose disease is in the relapsed or refractory stage, and who express a FLT3 mutation (FLT3mut+). The oral

The post Astellas’ gilteritinib secures EC approval to treat acute myeloid leukaemia appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply